期刊文献+

HIV-1辅受体配体的融合表达载体的构建及表达

Construction and Expression of the Bicistronic Expression Vector pCMV-R-K-S-K
下载PDF
导出
摘要 应用PCR扩增RANTES-KDEL基因,鉴定后与真核表达载体pCMV—S/K连接,构建成HIV-1辅受体的配体、趋化因子RANTES和SDF-1的融合表达载体pCMV-R—K-S—K,酶切鉴定和测序证明成功构建了pCMV—R—K—S—K融合表达载体。脂质体介导pCMV—R—K-S—K转染HeLa细胞,间接免疫荧光证实RANTES和SDF-1可高效表达于HeLa细胞。结果表明构建的pCMV—R—K—S—K融合表达载体能在HeLa细胞中高效表达,可用于下一步的HIV-1感染实验。 In order to construct bicistronic expression vector of RANTES and SDF-l,the ligands of HIV-1 principal coreceptors,RANTES-KDEL were amplified from pCMV-R-K by PCR and ligased with eukaryotic expression vector pCMV-S/K. The construction of pCMV-R-K-S-K was confirmed by enzymatic digestion and sequencing. Then pCMV-R-K-S-K transfection into HeLa cells was carried out by lipofectin. RAN TES and SDF-1 were showed expressed in HeLa cells by indirect immumofluo-rescence. The results show that pCMV-R-K-S-K was constructed and expressed in cell line HeLa successfully, which will contribute to gene therapy of HIV-1.
出处 《中国病毒学》 CSCD 2003年第1期23-26,T001,共5页 Virologica Sinica
基金 国家自然科学基金项目(39970695)
关键词 HIV-1 辅受体 趋化因子 融合表达载体 基因转染 HIV-1 Coreceptor Chmokine Bicistronic expression vector Transfection
  • 相关文献

参考文献12

  • 1Richman D D.HIV Therapy[J],1996.
  • 2Feng, Y;Broder, C. C;Kennedy, P. E.HIV-1 entry cofactor - functional cDNA cloning of a seven - transmembrane, G protein -coupled receptor[J],1996(5263).
  • 3Liu R;Paxton W A;Choe S.Homozygous defect in HIV-1 coreceptor accounts for resistance of some mnlUply-exposed individuals to HIV- 1 infection,1996(03).
  • 4Yan A G;Bai X F;Huang X F.Phenotypic knockout of HIV type 1 chemohne coreceptor CCR5 by intrakine as potentiol therapeutic approach for HIV-1 infection[J],1997(21).
  • 5Bagglioini M;Dewald B;Moser B.Interleukin-8 and related Chemotactic cytokines-CXC and CC chemokines[J],1994.
  • 6McKnieht A;Wilkinson D;Simmons G.In hibition of human immunodeficiency virus fusion by a monoclonal antiboby to a coreceptor(CXCR4) is both cell tepe and virus strain dependent,1997(02).
  • 7Olson W C;Rabut G E;Nagashima K A.Differential inhibmon of human immunodenciency virus type 1 fusion,gp120 bindingand CC-chemokine activity by monoclonal antibodies to CCR5[J],1999(05).
  • 8CHEN J D;Bei X F;Yang A G.Inactivation of HIV-1 Chemokine receptor CXCR4 by a novel intrakine strategy[J],1997(10).
  • 9Mosier D E;Picchio G R;Gulizia R J.Highly potent P ANTES analogues eidther prevent CCR5-using human immunodeficciency virus type 1 in fection in vivo or rapidly select for CX CR4-using variants[J],1999(05).
  • 10Dittmar M T;McKninght A;Simmons G.HIV-1 tropism and co-receptor use[J],1997(6616).

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部